Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | PTPRB | P23467 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.50 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.50 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | IDH1 | O75874 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31218457 | 0.90 | ALDH1A1 (0.45) | ALDH1A1HPGDPTPRBHSD17B10TAS1R3 | |
| SCHEMBL21979989 | 0.90 | ALDH1A1 (0.45) | ALDH1A1HPGDPTPRBHSD17B10TAS1R3 | |
| SCHEMBL18415477 | 0.84 | ALDH1A1 (0.61) | ALDH1A1HPGDTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL30487417 | 0.84 | ALDH1A1 (0.54) | ALDH1A1HPGDPTPRBHSD17B10TAS1R3 | |
| SCHEMBL11619402 | 0.84 | ALDH1A1 (0.44) | ALDH1A1HPGDPTPRBHSD17B10TAS1R3 | |
| SCHEMBL7620537 | 0.82 | HPGD (0.55) | ALDH1A1HPGDPTPRBHSD17B10MAPT | |
| SCHEMBL2902943 | 0.82 | ALDH1A1 (0.63) | ALDH1A1HPGDPTPRBHSD17B10MEN1 | |
| SCHEMBL1632654 | 0.81 | ALDH1A1 (0.48) | ALDH1A1HPGDMAPTMEN1KMT2A | |
| SCHEMBL20857699 | 0.80 | LMNA (0.56) | ALDH1A1HPGDPTPRBHSD17B10MAPT | |
| SCHEMBL6354671 | 0.80 | ALDH1A1 (0.44) | ALDH1A1MAPTMEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250026766-A1 | Thiazolopyridyl Amide Derivatives as DNA Polymerase Theta Inhibitors | BEIGENE, LTD. (KY) | 2025-01-23 | — | — | US | disclosed |
| EP-4463456-A1 | THIAZOLOPYRIDYL AMIDE DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | BeiGene, Ltd. (KY) | 2024-11-20 | — | — | EP | disclosed |
| CN-118510778-A | Thiazolopyridylamide derivatives as inhibitors of DNA polymerase θ | 百济神州有限公司 | 2024-08-16 | — | — | CN | disclosed |
| WO-2023134708-A1 | THIAZOLOPYRIDYL AMIDE DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | BEIGENE , LTD. (KY) | 2023-07-20 | — | — | WO | disclosed |
| EP-3326715-A1 | OXALIC ACID MONOAMIDE LIGAND, AND USES THEREOF IN COUPLING REACTION OF COPPER-CATALYZED ARYL HALOGEN SUBSTITUTE | Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences (CN) | 2018-05-30 | — | — | EP | disclosed |
| US-9487517-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-11-08 | — | — | US | disclosed |
| US-9487517-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-11-08 | — | — | US | disclosed |
| US-20160016956-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-01-21 | — | — | US | disclosed |
| US-9169254-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-10-27 | — | — | US | disclosed |
| US-9169254-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-10-27 | — | — | US | disclosed |
| US-7700636-B2 | Thiadiazole compounds and methods of use | AMGEN INC. (US) | 2010-04-20 | — | — | US | disclosed |
| US-20080269243-A1 | Thiadiazole compounds and methods of use | AMGEN INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080255145-A1 | Thiadiazole compounds and methods of use | AMGEN INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-7354944-B2 | Thiadiazole compounds and methods of use | AMGEN INC. (US) | 2008-04-08 | — | — | US | disclosed |
| EP-1809282-A2 | THIADIAZOLE COMPOUNDS AND METHODS OF USE | Amgen, Inc (US) | 2007-07-25 | — | — | EP | disclosed |
| US-20060154961-A1 | Thiadiazole compounds and methods of use | AMGEN INC. | 2006-07-13 | — | — | US | disclosed |
| WO-2006044860-A2 | THIADIAZOLE COMPOUNDS AND METHODS OF USE | AMGEN, INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| US-4101671-A | ANTIULCEROGENICS | BOEHRINGER INGELHEIM GMBH (DE) | 1978-07-18 | — | — | US | disclosed |
| US-RE29628-E | ANTIULCER, SECRETOLYTICS, ANTITUSSIVE | BOEHRINGER INGELHEIM GMBH (DT) | 1978-05-09 | — | — | US | disclosed |
| US-3950393-A | ANTIULCER, ANTISECRETORY, ANTITUSSIVE AGENTS | BOEHRINGER INGELHEIM GMBH (DT) | 1976-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255145-A1 | Thiadiazole compounds and methods of use | PDK2, PDK1, PANK2 | ALDH1A1 2285/4885HPGD 524/4885PTPRB 1193/4885 |
| US-20080269243-A1 | Thiadiazole compounds and methods of use | PDK2, PDK1, PANK2 | ALDH1A1 2285/4885HPGD 524/4885PTPRB 1193/4885 |
| US-20160016956-A1 | SPIROIMIDAZOLONE DERIVATIVE | WNK3, REN, SGK3 | ALDH1A1 836/4885HPGD 2068/4885PTPRB 1782/4885 |
| US-20250026766-A1 | Thiazolopyridyl Amide Derivatives as DNA Polymerase Theta Inhibitors | POLQ, POLK, POLI | ALDH1A1 2479/4885HPGD 1862/4885PTPRB 1604/4885 |
| US-20060154961-A1 | Thiadiazole compounds and methods of use | PDK2, PDK1, PANK2 | ALDH1A1 2285/4885HPGD 524/4885PTPRB 1193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.